Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Ovarian Neoplasms 10Recurrence 9Neoplasms 9Small Cell Lung Carcinoma 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma 5Multiple Myeloma 4Lymphoma, Follicular 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Mesothelioma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Kidney Neoplasms 3

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Adenocarcinoma × durvalumab × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡